The trial involves adults whose disease has come back or did not respond to earlier treatment (called “relapsed or refractory”) and who have either chronic lymphocytic leukemia or small lymphocytic lymphoma. The treatment being tested combines an intravenous antibody therapy known as rituximab, given for six cycles, with an oral tablet medication called venetoclax, which works by blocking a protein that helps cancer cells survive.
The purpose of the study is to compare how long patients stay free of disease progression when venetoclax is continued for a longer period versus stopping after the initial six‑month course. After the six cycles of the combination, participants are randomly assigned—by chance—to either keep taking venetoclax for up to about 20 cycles or to stop the drug. All participants are then monitored with regular doctor visits, blood tests, and scans to check for any return of disease or side effects. The main outcome measured is progression free survival, which counts the time from random assignment until the disease gets worse or the patient dies.
The Netherlands 
